Novo Nordisk Commits $506 Million for Ireland GLP-1 Expansion, Eases Semaglutide Shortage
Novo Nordisk announced a $506 million investment to expand its Athlone, Ireland facility, boosting oral GLP-1 drug capacity with phased completion by 2027–2028. The expansion aims to alleviate current semaglutide shortages and support global launch of Wegovy pills beyond the US.
1. $506 Million Investment and Facility Expansion
On March 2, Novo Nordisk announced a $506 million investment to expand its Athlone, Ireland facility. Construction began to increase production capacity for oral GLP-1 products including multiple semaglutide formulations, with completion scheduled between 2027 and 2028.
2. Tackling Semaglutide Shortages
The capacity boost follows recent semaglutide supply constraints that led to market shortages and spurred copycat drugs. Management expects the expansion to resolve production bottlenecks and stabilize global supply of Ozempic and Wegovy pills.
3. Global Rollout and Growth Outlook
In addition to meeting current US demand, the expanded plant will support launches of Wegovy pills in new international markets. Expanded capacity bolsters Novo Nordisk’s leadership in obesity care and diabetes management and underpins long-term revenue growth projections.